Lactobacillus crispatus LbV 88

If you could peer inside a perfectly healthy vaginal microbiome, you'd almost certainly find Lactobacillus crispatus sitting comfortably in charge. Scientists who study vaginal health have identified a handful of 'community state types' — essentially different neighbourhood profiles of bacteria — and the one linked to the best health outcomes by far is the one dominated by L. crispatus. The LbV 88 strain, developed and patented by AB-Biotics and also catalogued as DSM 22566, was isolated directly from the vaginal secretions of healthy pregnant women, then carefully selected for the properties that matter most: the ability to produce lactic acid, generate a natural antimicrobial compound called hydrogen peroxide, cling tightly to vaginal cells, and crowd out unwanted bacteria. Think of it as reintroducing the original sheriff back into a town that's fallen into disorder — once LbV 88 establishes itself, it starts enforcing the rules that keep the environment acidic, calm, and resistant to troublemakers. What makes this strain particularly exciting for researchers is that it can be taken by mouth. Rather than requiring an uncomfortable vaginal application, LbV 88 travels through the gut, migrates naturally through the perineum, and colonises the vaginal tract — the same pathway nature uses in the first place.

For women who have experienced bacterial vaginosis, the cycle is all too familiar: the antibiotic prescription works, the fishy odour and grey discharge disappear, and then — weeks or months later — it comes creeping back. That's because antibiotics clear out both the harmful bacteria and whatever beneficial lactobacilli were still hanging on, leaving an empty ecosystem that opportunistic bacteria are quick to re-colonise. This is precisely where LbV 88 shines. In a landmark double-blind clinical trial involving women diagnosed with BV, participants who consumed a multi-strain probiotic containing L. crispatus LbV 88 alongside their antibiotic course showed dramatically better results than those taking the antibiotic alone — the recovery rate in the probiotic group reached 100% compared with around 77% in the placebo group, as measured by established vaginal health scoring. Broader meta-analyses pooling data from multiple randomised trials have confirmed these findings, showing that the LbV 88-containing blend produces a significant shift in vaginal microbiome patterns toward a healthy, Lactobacillus-dominant state. Beyond BV, clinical research has found that high-level vaginal colonisation with L. crispatus is directly linked to a significant reduction in recurrent urinary tract infections — because a well-seeded vaginal environment creates a physical and chemical barrier that pathogenic bacteria like E. coli find very difficult to penetrate. For women navigating menopause, the hormonal drop in oestrogen naturally reduces vaginal glycogen (the food that beneficial lactobacilli feed on), making the vaginal microbiome more vulnerable. Replenishing L. crispatus through supplementation has shown promise in supporting microbial resilience during this transition, potentially helping to maintain comfort, moisture, and resistance to infection.

One of the most reassuring things about Lactobacillus crispatus LbV 88 is its safety profile — and that's not just marketing language. The strain was originally sourced from healthy humans, it belongs to a bacterial family with a long history of safe consumption in fermented foods and medical products, and it has been studied in clinical trials that included pregnant women without raising safety concerns. Mild and temporary digestive changes like light bloating or loose stools can occasionally occur when starting any probiotic, but these typically settle within the first few days. LbV 88 is most commonly found in oral capsule or powder sachet formulas, often combined with its companion strains — L. rhamnosus LbV 96, L. jensenii LbV 116, and L. gasseri LbV 150N — to create a more comprehensive vaginal Lactobacillus ecosystem. Clinical trials have used doses starting from around 4 billion CFU per day, with some formulations delivering up to 10 billion CFU daily for therapeutic effect. For best results, many practitioners suggest taking it consistently for at least four weeks, ideally beginning alongside or immediately after any antibiotic treatment to give it the best chance of successful colonisation. Women who are pregnant, immunocompromised, or managing a serious gynaecological condition should always consult their healthcare provider before starting any probiotic supplement, including this one. Beyond vaginal and urinary health, some emerging evidence suggests that supporting a healthy vaginal Lactobacillus environment through supplementation may have downstream benefits for reproductive outcomes and comfort during perimenopause — making LbV 88 a strain worth knowing by name.